#immunecheckpointinhibitor
LightNews LightNews
msklibrary.bsky.social
Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients With Metastatic Cancer

jamanetwork.com/journals/jam...

#MetastaticCancer #CancerTreatment #Immunotherapy #ImmuneCheckpointInhibitor #HealthInsurance #InsuranceMatters #CancerPolicy
#OncologyCareAccess
Immune Checkpoint Inhibitors and Survival Disparities by Insurance Coverage
This cross-sectional study uses nationwide cancer registry data to examine the association between the introduction of immune checkpoint inhibitors and survival disparities by health insurance coverag...
jamanetwork.com
July 21, 2025 at 2:19 PM
genesndiseases.bsky.social
This review highlights #ImmuneCheckpointInhibitor–induced #cardiotoxicity, detailing its mechanisms, clinical manifestations, and the need for cardio-immuno-oncology strategies to balance #anticancer efficacy with #cardiovascular safety.
#OpenAccess: doi.org/10.1016/j.ge...
Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology
April 15, 2026 at 5:56 AM
onco404.bsky.social
📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.

#Onco404 #Cancer #Kanser #MedSky #ImmuneCheckpointInhibitor #Immunotherapy #Keytruda #Opdivo #Yervoy #Imfinzi #Jemperli #Vocabulary
May 16, 2025 at 7:27 AM
jlbjournal.bsky.social
Haobei Ran, Lipan Zhang and colleagues report that "Single-cell transcriptomic analysis reveals RNA-binding protein dysregulation in #ImmuneCheckpointInhibitor –induced #Colitis"
Single-cell transcriptomic analysis reveals RNA-binding protein dysregulation in immune checkpoint inhibitor–induced colitis
RNA-binding protein dysregulation in immune checkpoint inhibitor–induced colitis.
doi.org
March 8, 2026 at 4:06 PM
profcelentyx.bsky.social
Breaking @cp-cancercell.bsky.social 'Preview' from Peter Matulich & @meganburgerphd.bsky.social on exciting new #Immunotherapy #ImmuneCheckpointInhibitor + #Lenvatinib #Tcells #Tregs Study |

www.cell.com/action/showP...
Circulating T cells fuel anti-PD-1 and lenvatinib efficacy
The mechanisms underlying synergy between checkpoint blockade and anti-angiogenic therapy remain elusive. In this issue of Cancer Cell, Guo et al. analyze hepatocellular carcinoma patients treated wit...
www.cell.com
January 30, 2025 at 6:36 PM
haoyin.bsky.social
#Metformin & #ImmuneCheckpointInhibitor anti-PD-L1 antibody synergistically normalize tumor vessels
⏬Primary tumor growth 🐭4T1 breast cancer
⏫#TumorVesselNormalization
⏬#VascularPermeability
⏫Mural cell coverage
⏫VE-cadherin
⏫CD8+ T cell

Heiichiro Udono lab #PNAS 2024
www.pnas.org/doi/10.1073/...
September 7, 2024 at 7:36 PM
northwell-journals.bsky.social
Molecular Medicine - Journal

Article in Press: HEATR1 deficiency enhanced gastric cancer cell PANoptosis to boost anti-tumor immunity | #MolecularMedicine #GastricCancer #PANoptosis #HEATR1 #ImmuneCheckpointInhibitor link.springer.com/article/10.1...
Fig. 6 HEATR1 knockdown PDOs were prone to PANoptosis and enhanced DC-primed CD8+ T cell expansion. A PDOs and PMBC-derived CD8+ T cells and immature DCs were obtained from the same patient. After pulsing with PDO supernatants, mature DCs were cocultured with CD8+ T cells.
September 10, 2026 at 3:38 PM
castltrastondrs.medsky.network
MedSky🧪#Cardiooncology There is a strong temporal association between Complete heart block & early mortality in people with #immunecheckpointinhibitor #myocarditis. Focusing on arrhythmogenic complications can be helpful in predicting outcomes for this group of critically ill individuals…
Complete Heart Block drives mortality in patients with ICI myocarditis: A new paradigm for assessing disease severity
September 26, 2023 at 2:25 PM
4040rec.bsky.social
#PharmaTimes #pharma #pharmaceuticals #BoehringerIngelheim #oncology #Subcutaneouspembrolizumab #NHS #NHShospitals #intravenousdelivery #immunotherapy #MHRA #immunecheckpointinhibitor #healthcareprofessionals #clinicianpreparationtime #NHSproductivity #oncologypatients
zurl.co/FWaFL
Subcutaneous pembrolizumab begins rollout across NHS hospitals - PharmaTimes
New one‑to‑two‑minute injection offers faster option for patients
pharmatimes.com
April 30, 2026 at 9:39 AM
haoyin.bsky.social
My continued biomedical education

#Atherosclerosis With #ImmuneCheckpointInhibitor Therapy: Evidence, Diagnosis, and Management

Note: Though atherosclerotic risks⏫with ICI, vascular risks in other organs vary

#JACCCardioOncology 2022
www.sciencedirect.com/science/arti...
July 23, 2024 at 8:06 PM
respcasereports.bsky.social
A Case of #Steroid-Dependent #ImmuneCheckpointInhibitor Pneumonitis Treated With Subcutaneous #Tocilizumab
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com
October 27, 2025 at 2:00 AM
thejidinnovations.bsky.social
From the March 2026 issue: Association of #immunecheckpointinhibitor induced #bullouspemphigoid with underlying cancer type: a lack of association with cancer tissue #COL17A1 mutations and dysregulation https://ow.ly/zNhA50Yzb4J #dermatology #dermsky
April 17, 2026 at 6:55 PM
thejidinnovations.bsky.social
Association of #immunecheckpointinhibitor induced #bullouspemphigoid with underlying cancer type: a lack of association with cancer tissue #COL17A1 mutations and dysregulation https://www.jidinnovations.org/article/S2667-0267(26)00001-9/fulltext #dermatology #dermsky
January 20, 2026 at 2:50 PM
genesndiseases.bsky.social
This study reveals cell types that influence #ImmuneCheckpointInhibitor response in #HepatocellularCarcinoma & identifies potential drug candidates using bulk & single-cell sequencing, offering a roadmap for novel #Immunotherapy strategies. #medsky

#OpenAccess: www.sciencedirect.com/science/arti...
October 9, 2025 at 12:59 PM
mol-biomed.bsky.social
#Letter
Immunogenomic analysis of concurrent lung cancer and tuberculosis reveals distinct immune milieu doi.org/10.1186/s435...

#Tuberculosis #LungCancer #ImmuneCheckpointInhibitor #ICI #immunity #multi_omic
Immunogenomic analysis of concurrent lung cancer and tuberculosis reveals distinct immune milieu - Molecular Biomedicine
Molecular Biomedicine -
doi.org
November 7, 2025 at 8:42 AM